Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.36 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122061 | 0.88 | BRD4 (0.42) | OPRM1BRPF1BRD4MAP2K4LMNA | |
| SCHEMBL3122069 | 0.88 | BRD4 (0.42) | OPRM1BRPF1BRD4MAP2K4LMNA | |
| SCHEMBL3135232 | 0.79 | MAP2K4 (0.39) | OPRM1BRPF1BRD4MAP2K4KCNT1 | |
| SCHEMBL3135240 | 0.79 | MAP2K4 (0.39) | OPRM1BRPF1BRD4MAP2K4KCNT1 | |
| SCHEMBL14582136 | 0.76 | SMN1; SMN2 (0.59) | OPRM1BRPF1BRD4MAP2K4LMNA | |
| SCHEMBL15576245 | 0.75 | ALDH1A1 (0.43) | PRMT6 | |
| SCHEMBL15576249 | 0.75 | SMN1; SMN2 (0.61) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL22268528 | 0.74 | EPHX2 (0.51) | OPRM1BRPF1BRD4MAP2K4LMNA | |
| SCHEMBL15054308 | 0.74 | HTR6 (0.51) | OPRM1BRPF1BRD4MAP2K4LMNA | |
| SCHEMBL15946017 | 0.73 | OPRM1 (0.45) | OPRM1BRPF1BRD4MAP2K4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | OPRM1 4519/4885BRPF1 3793/4885BRD4 2332/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | OPRM1 4519/4885BRPF1 3793/4885BRD4 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.